[{"id":"a6ff77bf-43f0-491c-b636-703839e573f4","acronym":"","url":"https://clinicaltrials.gov/study/NCT05109442","created_at":"2021-11-05T12:53:17.433Z","updated_at":"2024-07-02T16:35:38.810Z","phase":"Phase 1/2","brief_title":"Study to Assess AFM24 in Combination With Atezolizumab in Selected Advanced/Metastatic EGFR-expressing Cancers","source_id_and_acronym":"NCT05109442","lead_sponsor":"Affimed GmbH","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR T790M • EGFR wild-type • EGFR positive","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR T790M • EGFR wild-type • EGFR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • AFM24"],"overall_status":"Recruiting","enrollment":" Enrollment 148","initiation":"Initiation: 11/19/2021","start_date":" 11/19/2021","primary_txt":" Primary completion: 09/30/2024","primary_completion_date":" 09/30/2024","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2023-08-29"},{"id":"d4a29523-440e-4515-8e78-e0bd662648f6","acronym":"","url":"https://clinicaltrials.gov/study/NCT04259450","created_at":"2021-01-18T20:42:00.797Z","updated_at":"2024-07-02T16:35:39.230Z","phase":"Phase 1/2","brief_title":"Study to Assess AFM24 in Advanced Solid Cancers","source_id_and_acronym":"NCT04259450","lead_sponsor":"Affimed GmbH","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS wild-type • RAS wild-type","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS wild-type • RAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AFM24"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 85","initiation":"Initiation: 04/07/2020","start_date":" 04/07/2020","primary_txt":" Primary completion: 07/12/2023","primary_completion_date":" 07/12/2023","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2023-08-23"}]